Recent meta-analyses [157,158] of clinical trials utilizing PARPi for BC patients showed efficacy in improving OS, as well as improved PFS for TNBC, HR-positive, and or HER2-negative patients, as well as those with BRCA1/2 germline mutations. This evidence concerns the gene ERBB2 and breast cancer.